Chardan Capital starts Senti Biosciences coverage with 'buy'

Senti Biosciences Holdings

23/09/2022 16:33

** Brokerage Chardan Capital Markets starts coverage of
cancer therapies developer Senti Biosciences Inc  SNTI.O  with
"buy" rating and $12 PT
    ** Brokerage sees potential in company's gene therapy
platform and cell therapy pipeline to treat solid tumors and
address several limitations in current therapies
    ** Scope for future collaborations in gene and cell
therapies for company's existing partnerships with Roche Holding
AG  ROG.S  and Bayer AG  BAYGn.DE  - Chardan
    ** Brokerage believes SNTI's manufacturing capabilities,
beyond its internal pipeline, could be leveraged for
biomanufacturing 
    ** Company's shares down 4.4% at $1.33, in line with broader
markets; including session's losses, stock down ~86% YTD
 (Reporting by Pratik Jain)
 ((Pratik.Jain@thomsonreuters.com))